Tumor Lysis Syndrome

A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.

Also Known As:

Networked: 510 relevant articles (27 outcomes, 19 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Hyperuricemia
2.	Acute Kidney Injury (Acute Renal Failure)
3.	Hematologic Neoplasms (Hematological Malignancy)
4.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
5.	Leukemia

Experts

1.	Byrd, John C: 7 articles (12/2014 - 08/2003)
2.	Phelps, Mitch A: 5 articles (10/2013 - 03/2009)
3.	Grever, Michael R: 5 articles (10/2013 - 03/2009)
4.	Darmon, Michael: 4 articles (10/2014 - 09/2008)
5.	Cairo, Mitchell S: 4 articles (11/2013 - 12/2002)
6.	Johnson, Amy J: 4 articles (10/2013 - 03/2009)
7.	Pession, Andrea: 4 articles (08/2011 - 01/2005)
8.	Kobayashi, Ryoji: 3 articles (07/2015 - 07/2005)
9.	Schlemmer, Benoit: 3 articles (06/2015 - 09/2008)
10.	Canet, Emmanuel: 3 articles (06/2015 - 08/2013)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Tumor Lysis Syndrome:

1.	rasburicase (Elitek)FDA Link 02/01/2009 - "Rasburicase is very effective in the prevention of acute tumour lysis syndrome. " 01/01/2013 - "One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies." 06/01/2012 - "A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome." 12/01/2011 - "Recently, a number of studies have demonstrated the effectiveness of a single reduced dose of rasburicase for the management of tumor lysis syndrome (TLS) in adults. " 03/01/2014 - "Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome."
2.	Uric Acid (Urate)IBA 10/01/2015 - "Serum uric acid (sUA) control is of key relevance in tumor lysis syndrome (TLS) prevention as it correlates with both TLS and renal event risk. " 01/01/2015 - "Uric acid and the prediction models of tumor lysis syndrome in AML." 12/01/2014 - "Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, and control of serum uric acid level (S-UA) is most important. " 09/01/2013 - "Prophylaxis and therapy of the tumor lysis syndrome consists of hydration, lowering of uric acid and the management of electrolyte disturbances. " 01/01/2013 - "Her initial chemotherapeutic course was complicated by tumor lysis syndrome manifested by elevated serum uric acid and was treated effectively with hyperhydration and alkalization of intravenous fluids. "
3.	Urate Oxidase (Uricase)IBA 10/01/2004 - "Tumor lysis syndrome (TLS) occurred in 9% during induction phase with a high mortality of 44% (urate-oxidase was available only at the end of the study). " 01/01/2014 - "Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome." 08/01/2007 - "Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? " 07/01/1998 - "Prophylactic use of urate-oxidase in all patients with advanced stage NHL might limit the incidence of tumor lysis syndrome. " 01/01/1985 - "Urate-oxidase as hypouricemic agent in a case of acute tumor lysis syndrome."
4.	sevelamer (RenaGel)FDA Link 07/01/2015 - "Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome." 07/01/2008 - "Sevelamer appears to be effective and tolerable for the treatment of hyperphosphatemia associated with tumor lysis syndrome." 07/01/2008 - "Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children." 07/01/2015 - "Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia." 07/01/2008 - "To describe the safety of sevelamer in children with hyperphosphatemia secondary to tumor lysis syndrome and the serum phosphate concentrations observed following its administration. "
5.	Allopurinol (Remid)FDA LinkGeneric 12/01/2011 - "The strategy against tumour lysis syndrome (TLS) had been hyperhydration, urine alkalinization, and allopurinol. " 10/01/2006 - "The patient's hospital course was complicated by tumor lysis syndrome that was managed by hydration and allopurinol. " 01/01/2005 - "The status of allopurinol in the management of tumor lysis syndrome: a clinical review." 09/01/2004 - "In addition, she received allopurinol 300 mg daily for prevention of tumor lysis syndrome (TLS). " 04/01/2001 - "Role of intravenous allopurinol in the management of acute tumor lysis syndrome."
6.	lenalidomide (CC 5013)FDA Link 01/01/2013 - "This review discusses the potential mechanism of action and efficacy of lenalidomide, alone or in combination, in treatment of CLL and its toxic effects such as tumor lysis syndrome (TLS) and tumor flare reaction (TFR), that make its management different from other hematologic malignancies. " 06/01/2012 - "The erratic but serious incidence of tumor lysis syndrome and/or tumor flare reactions provides challenges in the incorporation of lenalidomide in the management of previously untreated lymphoma patients with bulky adenopathy. " 02/01/2011 - "The erratic but serious incidence of tumor lysis syndrome and/or tumor flare reactions provides challenges in the incorporation of lenalidomide in the management of previously untreated CLL or CLL/lymphoma patients with bulky adenopathy. " 11/01/2007 - "Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia." 08/01/2010 - "In addition to the known adverse effects associated with lenalidomide (e.g., myelosuppression, rash, fatigue), some unique effects (e.g., tumor flare reactions, tumor lysis syndrome) have arisen during clinical studies of CLL. "
7.	bortezomib (Velcade)FDA Link 05/01/2014 - "Tumor-lysis syndrome occurred during the first course of bortezomib-containing treatment among all the patients. " 05/01/2014 - "However, bortezomib treatment for myeloma is often associated with tumor-lysis syndrome. " 08/01/2010 - "The patient was complicated by tumor lysis syndrome (TLS) after receiving bortezomib therapy twice. " 02/01/2015 - "Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment." 05/01/2014 - "Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients."
8.	Dexamethasone (Maxidex)FDA LinkGeneric 06/01/2008 - "This is the first documented peri-operative death due to tumour lysis syndrome after administration of dexamethasone. " 06/01/2008 - "Fatal peri-operative acute tumour lysis syndrome precipitated by dexamethasone." 09/01/2006 - "Tumor lysis syndrome induced by dexamethasone." 06/01/2008 - "The use of dexamethasone for prophylaxis against postoperative nausea and vomiting was the likely aetiology of the acute tumour lysis syndrome in this case. " 08/01/2001 - "Acute tumor lysis syndrome in a patient with multiple myeloma treated with dexamethasone monotherapy."
9.	Thalidomide (Thalomid)FDA Link 01/01/2006 - "Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma." 03/01/2004 - "Tumor lysis syndrome in a multiple myeloma treated with thalidomide." 04/15/2002 - "Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma." 12/01/2006 - "Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma." 06/01/2008 - "Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome."
10.	Carboplatin (JM8)FDA LinkGeneric 11/01/2002 - "Despite salvage chemotherapy with a P-IMVP16/CBDCA regimen, the patient died of multiple organ failure due to tumor lysis syndrome. " 01/01/2011 - "Tumor lysis syndrome in a patient with merkel cell carcinoma and provoked pathologic sequence of acute kidney injury, reduced clearance of carboplatin and fatal pancytopenia." 06/01/2010 - "Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer."

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2012 - "With intensive chemotherapy, complete remission was rapidly achieved, without life-threatening tumor lysis syndrome. " 12/01/1995 - "The patient suffered from tumor lysis syndrome after chemotherapy, but complete remission was achieved by dialysis." 07/01/2010 - "Treatment for tumor lysis syndrome and chemotherapy were initiated, and he progressively improved. " 12/01/2011 - "This study highlights useful information for identifying patients with malignancies at risk for tumor lysis syndrome (TLS) before starting chemotherapy." 11/01/2015 - "Tumor lysis syndrome, a complication of anticancer chemotherapy, results from rapid lysis of malignant cells. "
2.	Renal Dialysis (Hemodialysis) 07/01/2010 - "Life-threatening hyperacute tumor lysis syndrome requiring hemodialysis on day 1 was observed in one patient. " 12/10/2009 - "If patients tolerated treatment during week 1, dose escalation occurred during week 2. Dose escalation did not occur in four patients, as a result of severe tumor lysis syndrome; three of these patients required hemodialysis. " 09/21/2009 - "Tumor lysis syndrome was suspected and intensive hemodialysis was performed. " 01/01/2005 - "prophylaxis and treatment of tumor lysis syndrome consist of adequate hydration of the patients (3 l fluid/m2/day) in order to maintain urine production of > or =100 ml/h, controlled alkalinisation (urine pH 7.0-7.5) and, if necessary, extracorporeal therapy (intermittent or continuous hemodialysis or hemodiafiltration). " 07/01/1998 - "Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature."
3.	Aftercare (After-Treatment) 09/01/2015 - "One patient developed a catecholamine crisis and tumor lysis syndrome within hours of treatment, requiring intensive care unit (ICU) support, and another developed a catecholamine crisis 3 days after treatment, requiring hospitalization. " 01/01/1987 - "Tumour lysis syndrome, manifested by various metabolic derangements, is a known complication after treatment of some lymphoid malignancies. " 03/01/2013 - "After treatment, anuria occurred, and laboratory examinations revealed a diagnosis of tumor lysis syndrome (TLS). " 04/01/1997 - "[Tumor lysis syndrome after treatment for mediastinal non-Hodgkin's lymphoma]." 12/12/2013 - "One patient with chronic lymphocytic leukemia (CLL) obtained an ongoing complete remission after treatment with allogeneic anti-CD19-CAR T cells, another CLL patient had tumor lysis syndrome as his leukemia dramatically regressed, and a patient with mantle cell lymphoma obtained an ongoing partial remission. "
4.	Remission Induction 10/01/1988 - "[Acute tumor lysis syndrome (ATLS) during remission induction treatment of Burkitt's lymphoma: study of 26 patients]."
5.	Radiotherapy 12/20/2008 - "Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer." 01/01/2005 - "patients with solid tumors rarely develop a tumor lysis syndrome during anti-neoplastic therapy (chemo-, hormonal-, steroid therapy, radiotherapy). " 01/01/2004 - "Acute tumor lysis syndrome caused by palliative radiotherapy in patients with diffuse large B-cell lymphoma." 05/01/2012 - "Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis." 10/01/2007 - "Tumor lysis syndrome (TLS) is a complication of hematological and others malignancies, caused by massive tumor cell lysis due to chemotherapy, immunotherapy, radiotherapy. "